Studies on the behaviour of semicarbazide-sensitive amine oxidase in Sprague-Dawley rats treated with the monoamine oxidase inhibitor tranylcypromine
The possibility that increased levels of the activity of the semicarbazide-sensitive amine oxidase (SSAO) might, to some extent, compensate for the loss of monoamine oxidase (MAO) activity in the atypical form of Norrie Disease, was examined using the rat as a model. Long-term treatment with the MAO inhibitor tranylcypromine (1 mg/kg/day) resulted in sustained inhibition of MAO-A and MAO-B activities in liver and brain. After one week, the SSAO activity in heart had increased by 79% above the control levels. This increase was maintained for 3 weeks. Since such alterations might result from enzyme induction, the turnover of the enzyme was studied in cultured cells from rat aortic smooth muscle. The time-course of recovery of enzyme activity following irreversible inhibition by MDL 72145 corresponded to a half-life of approximately 6 days for this process.
KeywordsMonoamine Oxidase Amine Oxidase SSAO Activity Plasma Amine Oxidase Inhibitor Tranylcypromine
Unable to display preview. Download preview PDF.
- Lewinsohn R (1984) Mammalian monoamine oxidising enzymes, with special reference to benzylamine oxidase in human tissues. Brazil J Med Biol Res 17: 223–256Google Scholar
- McEwen CM Jr (1972) The soluble monoamine oxidase of human plasma and sera. Adv Biochem Psychopharmacol 5: 51–165Google Scholar
- Suzuki O, Matsumoto T (1984) Some properties of benzylamine oxidase in human aorta. Biogenic Amines 1: 249–257Google Scholar
- Tipton KF (1985) Determination of monoamine oxidase. Meth Find Exp Clin Pharmacol 7: 361–367Google Scholar
- Warburg M (1966) Norries disease: a congenital, progressive, occuloacoustic, cerebral degeneration. Acta Opthalmol (Copenh) [Suppl] 89: 1–47Google Scholar